Univariate and multivariate Cox regression analyses of PFS and OS for combined training (TT3A, UARK2003-33) and test sets (TT3B, UARK 2006-66)
| Variable . | n/N (%) . | PFS . | OS . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P* . | HR (95% CI) . | P* . | ||
| Univariate Cox regression analysis† | |||||
| Age ≥ 65 y | 71/270 (26) | 1.30 (0.81-2.11) | .281 | 1.02 (0.57-1.80) | .957 |
| Albumin level < 3.5 g/dL | 89/269 (33) | 2.03 (1.29-3.20) | .002 | 1.93 (1.16-3.23) | .012 |
| B2M level ≥ 3.5 mg/L | 133/267 (50) | 2.01 (1.27-3.19) | .003 | 1.96 (1.16-3.30) | .011 |
| ISS Stage III | 68/267 (25) | 2.10 (1.32-3.33) | .002 | 2.09 (1.24-3.52) | .006 |
| Creatinine level ≥ 2.0 mg/dL | 22/269 (8) | 2.07 (1.09-3.93) | .025 | 2.08 (1.02-4.22) | .043 |
| CRP level ≥ 8 mg/L | 98/269 (36) | 2.05 (1.31-3.20) | .002 | 1.93 (1.17-3.20) | .010 |
| Hb level < 10 g/dL | 79/269 (29) | 2.19 (1.39-3.44) | < .001 | 2.33 (1.40-3.88) | .001 |
| LDH level ≥ 190 U/L | 70/269 (26) | 3.99 (2.55-6.24) | < .001 | 4.13 (2.49-6.84) | < .001 |
| Cytogenetic abnormalities | 104/267 (39) | 2.36 (1.51-3.70) | < .001 | 3.43 (2.03-5.80) | < .001 |
| Baseline 70-gene high risk | 49/270 (18) | 4.22 (2.65-6.71) | < .001 | 5.00 (3.00-8.35) | < .001 |
| GEP CD-1 subgroup | 16/270 (6) | 1.00 (0.36-2.74) | .999 | 1.33 (0.48-3.69) | .579 |
| GEP CD-2 subgroup | 32/270 (12) | 0.53 (0.21-1.31) | .168 | 0.40 (0.13-1.29) | .126 |
| GEP HY subgroup | 74/270 (27) | 0.97 (0.59-1.61) | .921 | 0.98 (0.55-1.73) | .934 |
| GEP LB subgroup | 28/270 (10) | 0.39 (0.14-1.08) | .069 | 0.39 (0.12-1.24) | .110 |
| GEP MF subgroup | 18/270 (7) | 2.31 (1.19-4.49) | .014 | 2.18 (1.03-4.58) | .040 |
| GEP MS subgroup | 33/270 (12) | 1.17 (0.60-2.27) | .647 | 0.95 (0.43-2.10) | .907 |
| GEP PR subgroup | 34/270 (13) | 2.53 (1.47-4.34) | < .001 | 2.92 (1.62-5.25) | < .001 |
| GEP proliferation index ≥ 10 | 34/270 (13) | 3.67 (2.25-5.97) | < .001 | 3.91 (2.29-6.69) | < .001 |
| GEP TP53 deletion | 29/270 (11) | 2.71 (1.54-4.76) | < .001 | 3.40 (1.87-6.19) | < .001 |
| Baseline 80-gene high risk | 28/270 (10) | 6.60 (3.91-11.15) | < .001 | 8.76 (4.99-15.38) | < .001 |
| Post-Bz 80-gene high risk | 48/270 (18) | 5.05 (3.20-7.97) | < .001 | 6.15 (3.70-10.23) | < .001 |
| FISH 1q21 copy number (2,3,4) | 107 | 1.67 (0.96-2.88) | .068 | 1.92 (1.10-3.36) | .022 |
| PSMD4 discretized levels (2,3,4) | 269 | 1.67 (1.28-2.18) | < .001 | 1.95 (1.48-2.58) | < .001 |
| Multivariate Cox regression analysis‡ | |||||
| Albumin level < 3.5 g/dL | 89/269 (33) | 1.90 (1.20-2.99) | .006 | 1.73 (1.03-2.90) | .038 |
| Baseline 80-gene high risk | 28/269 (10) | 3.77 (2.14-6.62) | < .001 | 5.25 (2.83-9.75) | < .001 |
| LDH level ≥ 190 U/L | 70/269 (26) | 2.94 (1.81-4.76) | < .001 | 2.63 (1.51-4.60) | < .001 |
| Variable . | n/N (%) . | PFS . | OS . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P* . | HR (95% CI) . | P* . | ||
| Univariate Cox regression analysis† | |||||
| Age ≥ 65 y | 71/270 (26) | 1.30 (0.81-2.11) | .281 | 1.02 (0.57-1.80) | .957 |
| Albumin level < 3.5 g/dL | 89/269 (33) | 2.03 (1.29-3.20) | .002 | 1.93 (1.16-3.23) | .012 |
| B2M level ≥ 3.5 mg/L | 133/267 (50) | 2.01 (1.27-3.19) | .003 | 1.96 (1.16-3.30) | .011 |
| ISS Stage III | 68/267 (25) | 2.10 (1.32-3.33) | .002 | 2.09 (1.24-3.52) | .006 |
| Creatinine level ≥ 2.0 mg/dL | 22/269 (8) | 2.07 (1.09-3.93) | .025 | 2.08 (1.02-4.22) | .043 |
| CRP level ≥ 8 mg/L | 98/269 (36) | 2.05 (1.31-3.20) | .002 | 1.93 (1.17-3.20) | .010 |
| Hb level < 10 g/dL | 79/269 (29) | 2.19 (1.39-3.44) | < .001 | 2.33 (1.40-3.88) | .001 |
| LDH level ≥ 190 U/L | 70/269 (26) | 3.99 (2.55-6.24) | < .001 | 4.13 (2.49-6.84) | < .001 |
| Cytogenetic abnormalities | 104/267 (39) | 2.36 (1.51-3.70) | < .001 | 3.43 (2.03-5.80) | < .001 |
| Baseline 70-gene high risk | 49/270 (18) | 4.22 (2.65-6.71) | < .001 | 5.00 (3.00-8.35) | < .001 |
| GEP CD-1 subgroup | 16/270 (6) | 1.00 (0.36-2.74) | .999 | 1.33 (0.48-3.69) | .579 |
| GEP CD-2 subgroup | 32/270 (12) | 0.53 (0.21-1.31) | .168 | 0.40 (0.13-1.29) | .126 |
| GEP HY subgroup | 74/270 (27) | 0.97 (0.59-1.61) | .921 | 0.98 (0.55-1.73) | .934 |
| GEP LB subgroup | 28/270 (10) | 0.39 (0.14-1.08) | .069 | 0.39 (0.12-1.24) | .110 |
| GEP MF subgroup | 18/270 (7) | 2.31 (1.19-4.49) | .014 | 2.18 (1.03-4.58) | .040 |
| GEP MS subgroup | 33/270 (12) | 1.17 (0.60-2.27) | .647 | 0.95 (0.43-2.10) | .907 |
| GEP PR subgroup | 34/270 (13) | 2.53 (1.47-4.34) | < .001 | 2.92 (1.62-5.25) | < .001 |
| GEP proliferation index ≥ 10 | 34/270 (13) | 3.67 (2.25-5.97) | < .001 | 3.91 (2.29-6.69) | < .001 |
| GEP TP53 deletion | 29/270 (11) | 2.71 (1.54-4.76) | < .001 | 3.40 (1.87-6.19) | < .001 |
| Baseline 80-gene high risk | 28/270 (10) | 6.60 (3.91-11.15) | < .001 | 8.76 (4.99-15.38) | < .001 |
| Post-Bz 80-gene high risk | 48/270 (18) | 5.05 (3.20-7.97) | < .001 | 6.15 (3.70-10.23) | < .001 |
| FISH 1q21 copy number (2,3,4) | 107 | 1.67 (0.96-2.88) | .068 | 1.92 (1.10-3.36) | .022 |
| PSMD4 discretized levels (2,3,4) | 269 | 1.67 (1.28-2.18) | < .001 | 1.95 (1.48-2.58) | < .001 |
| Multivariate Cox regression analysis‡ | |||||
| Albumin level < 3.5 g/dL | 89/269 (33) | 1.90 (1.20-2.99) | .006 | 1.73 (1.03-2.90) | .038 |
| Baseline 80-gene high risk | 28/269 (10) | 3.77 (2.14-6.62) | < .001 | 5.25 (2.83-9.75) | < .001 |
| LDH level ≥ 190 U/L | 70/269 (26) | 2.94 (1.81-4.76) | < .001 | 2.63 (1.51-4.60) | < .001 |
95% CI indicates 95% confidence interval; B2M, β2-microglobulin; ISS, International Staging System; CRP, C-reactive protein; and Hb, hemoglobin.
Determined with Wald chi-square test in Cox regression.
All univariate P values were reported regardless of significance. Variables with univariate P < .10 were considered for selection in the multivariate analysis.
Multivariate model uses stepwise selection with entry level 0.1 and variable remains if meets the 0.05 level.